Form 4 for BCAX Bicara Therapeutics Inc.
Accepted 2026-08-12 16:19:21 ET · period of report 2026-08-10 · accession 0001470831-26-000814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Hyep Ivan | CFO | M - OptEx | $3.79 | +12.5K | 142.4K | +10% | +$47.4K |
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Hyep Ivan | CFO | S - Sale+OE | $27.97 | -12.5K | 129.9K | -9% | -$349.6K |
| DT | 2026-08-12 16:19 | 2026-08-10 | BCAX | Hyep Ivan | CFO | M - OptEx | $0.00 | -12.5K | 26.3K | -32% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-10 | M | A | 12,500 | $3.79 | 142,355 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. |
| 2 | Common | Common Stock | 2026-08-10 | S | D | 12,500 | $27.97 | 129,855 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.675 to $28.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-08-10 | M | D | 12,500 | $0.00 | 26,336 | D | $3.79 · — to 2033-04-05 | 12,500 Common Stock | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026. (F3) The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. |